Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Extension Study of Inhaled Treprostinil in Subjects With Fibrotic Lung Disease

NCT: NCT04905693 · ENROLLING_BY_INVITATION

NCT IDNCT04905693
StatusENROLLING_BY_INVITATION
Start Date2022-09-06
SponsorUnited Therapeutics (INDUSTRY)
First posted
Last updated

Brief Summary

Study RIN-PF-302 is designed to evaluate the long-term safety and tolerability of inhaled treprostinil in subjects with idiopathic pulmonary fibrosis or progressive pulmonary fibrosis.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑